Literature DB >> 23293206

Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis.

Joseph E Maakaron1, Maria Domenica Cappellini, Giovanna Graziadei, Jad Bou Ayache, Ali T Taher.   

Abstract

Patients with thalassemia are often exposed to several risk factors for developing hepatocellular carcinoma (HCC) due to their repeated transfusions. However, even transfusion-independent patients with thalassemia intermedia (TI) can develop HCC, which is mainly attributed to a state of iron overload. We report here two cases and review the literature for the association between TI and HCC. Along with our cases, a total of 36 cases of HCC in thalassemic patients were reported in the literature. Of these, 22 (61%) were TI patients with 6 (27%) of them being hepatitis B and C negative. There was no consistency in their characteristics; therefore, we recommended screening thresholds for HCC in TI patients based on their total liver iron concentration (LIC).

Entities:  

Mesh:

Year:  2013        PMID: 23293206

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  13 in total

Review 1.  Management of non-transfusion-dependent thalassemia: a practical guide.

Authors:  Ali T Taher; Maria Domenica Cappellini
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

2.  Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells.

Authors:  Zhizhen Dong; Min Yao; Li Wang; Xiaodi Yan; Xing Gu; Yun Shi; Ninghua Yao; Liwei Qiu; Wei Wu; Dengfu Yao
Journal:  Tumour Biol       Date:  2013-12

3.  IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.

Authors:  Min Yao; Li Wang; Junling Yang; Xiaodi Yan; Yin Cai; Dengfu Yao
Journal:  Tumour Biol       Date:  2016-09-13

Review 4.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

Review 5.  Non-transfusion-dependent thalassemias.

Authors:  Khaled M Musallam; Stefano Rivella; Elliott Vichinsky; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

Review 6.  Cancer cells with irons in the fire.

Authors:  Laura M Bystrom; Stefano Rivella
Journal:  Free Radic Biol Med       Date:  2014-05-14       Impact factor: 7.376

Review 7.  β-Thalassemia.

Authors:  Raffaella Origa
Journal:  Genet Med       Date:  2016-11-03       Impact factor: 8.822

Review 8.  β-Thalassemia Intermedia: A Bird's-Eye View.

Authors:  Anthony Haddad; Paul Tyan; Amr Radwan; Naji Mallat; Ali Taher
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

Review 9.  Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia.

Authors:  Paul I Tyan; Amr H Radwan; Assaad Eid; Anthony G Haddad; David Wehbe; Ali T Taher
Journal:  Biomed Res Int       Date:  2014-07-09       Impact factor: 3.411

Review 10.  Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence.

Authors:  Alessandra Mangia; Davide Bellini; Umberto Cillo; Andrea Laghi; Giuseppe Pelle; Vanna Maria Valori; Eugenio Caturelli
Journal:  BMC Gastroenterol       Date:  2020-08-03       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.